Previous 10 | Next 10 |
STAAR Surgical press release (NASDAQ:STAA): Q4 Non-GAAP EPS of $0.19 beats by $0.03. Revenue of $59M (+28.3% Y/Y) misses by $0.21M. For further details see: STAAR Surgical Non-GAAP EPS of $0.19 beats by $0.03, revenue of $59M misses by $0.21M
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the fourth quarter and fiscal year ended December 31, 2021. Fourth Quarter 2021 Overview ...
STAAR Surgical has exhibited tremendous growth in recent years, and that performance continued throughout 2021. Long term, the company's operational prospects probably are bullish and that's great for investors. But shares today look drastically overpriced and investors should tre...
With STAAR Surgical (NASDAQ: STAA) shares down more than 50% in the past six months, stockholders are in sore need of some good news. Despite the company's decent pace of revenue and earnings growth and minimal debt, shareholders may not have much to look forward to right now from t...
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2021 on We...
Achieves 40% Growth Y/Y with Full Year 2021 Net Sales of Approximately $230 Million Fourth Quarter Net Sales Approximately $59 Million STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery s...
This is an evaluation of likely coming stock prices, not an appraisal of STAA’s product line or management’s competitive abilities. They’re already evaluated by big-$ investment analysts and portfolio managers. The buys they urge as volume “block trades...
Image source: The Motley Fool. STAAR Surgical Company (NASDAQ: STAA) Q3 2021 Earnings Call Nov 3, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: STAAR Surgical Company (STAA) Q3 2021 Earnings Call Transcript
STAAR Surgical Company (STAA) Q3 2021 Earnings Conference Call Nov 03, 2021 04:30 PM ET Company Participants Brian Moore - Vice President, Investor, Media Relations & Corporate Development Caren Mason - President & Chief Executive Officer Patrick Williams - Chief Financial Officer Con...
STAAR Surgical (NASDAQ:STAA): Q3 Non-GAAP EPS of $0.21 beats by $0.04; GAAP EPS of $0.12 beats by $0.02. Revenue of $53.35M (+13.3% Y/Y) misses by $4.51M. Press Release For further details see: STAAR Surgical EPS beats by $0.04, misses on revenue
News, Short Squeeze, Breakout and More Instantly...
STAAR Surgical Company Company Name:
STAA Stock Symbol:
NASDAQ Market:
STAAR Surgical Company Website:
2024-07-14 17:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with Patrick F. Will...
2024-05-24 07:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...